NaviFUS News

 On October 13, 2020, the Focused Ultrasound Foundation and the Society for Neuro-Oncology (SNO) hosted a webinar on ultrasound-mediated blood-brain barrier disruption (BBBD). Multiple clinical trials are ongoing or planned to investigate this rapidly developing approach to enhance small molecule, antibody, and cell delivery to brain tumors. This webinar brought together the pharmaceutical and biotech companies that are advancing this technology with investigators to provide an update on opportunities and challenges for using ultrasound BBBD to deliver therapeutics to brain tumor patients.Five brief presentations by experts across the field were followed by a Q&A discussion.   WATCH THE RECORDING >

 2020 年 10 月 13 日，SNO神經腫瘤學會/FUS基金會舉辦關於聚焦式超音波破壞血腦屏障（BBBD） 的網路研討會。目前有多項計畫與正在進行的臨床試驗，在研究這種迅速發展的方法，來增強小分子、抗體和細胞向腦腫瘤的傳遞。 此網路研討聚集製藥公司及生物技術公司，提供研究人員們一起推動這項技術，以及有關使用聚焦式超音波破壞血腦屏障（BBBD）於腦腫瘤患者上的最新機會與挑戰資訊。五位領域專家簡報，隨後進行問答討論。  觀看更多>

Genovate Biotech (TPEX:4130) subsidiary and Taiwan-based focused ultrasound (FUS) manufacturer NaviFUS Corporation is pleased to announce the start of its clinical trial (NCT04446416) for the combination of FUS plus bevacizumab therapy. Researchers at Linkou Chang Gung Memorial Hospital are investigating the use of Neuronavigation-guided FUS to repeatedly and temporarily open the blood-brain barrier (BBB) and enhance bevacizumab's efficacy in patients with recurrent glioblastoma (rGBM). To date, the first patient has been enrolled and is undergoing treatment. Led by neurosurgeon Dr. Kuo-Chen Wei at Linkou Chang Gung Memorial Hospital, the clinical trial will evaluate the safety and preliminary efficacy of repeated FUS-induced BBB opening with bevacizumab using the company's NaviFUS System. NaviFUS System utilizes neuronavigation and prior patient CT/MR images to guide the FUS energy. Additionally, the system includes a real-time acoustic emissions monitoring function that can p...

Genovate Biotech (4130) subsidiary NaviFUS has scored some more good news on its R&D front. Not long after receiving approval for its rGBM clinical trial in Taiwan, NaviFUS has also received approval to begin human clinical trials for Alzheimer’s Disease treatment in Australia. The company is a world-leading developer of transcranial focused ultrasound (FUS) technology specializing in safely and non-invasively delivering FUS energy into the brain. Genovate has stated that the NaviFUS system can be used to treat Central Nervous System (CNS) diseases and plans to conduct its first clinical trial for the treatment of Alzheimer's Disease in Australia to evaluate safety and efficacy. This trial was approved by the Innovations Committee and Ethics Committee in mid-August at The Alfred Hospital in Monash University, one of the most prestigious academic-medical institutions in Australia. NaviFUS System is the world’s first FUS device that combines Neuronavigation – an optical tracking ...

NaviFUS Corporation, Genovate Biotech (4130) subsidiary and high-end medical device company, completed its first safety and efficacy clinical trial for its focused ultrasound (FUS) device, NaviFUS System, last year in June. The trial consisted of six patients with Recurrent Glioblastoma (rGBM), and results showed that the system can precisely open the blood-brain barrier (BBB) with safe recovery afterwards. Because the trial conducted both safety and feasibility testing, Genovate stated that the phase of the trial was equivalent to a clinical phase I/IIa, setting the stage for its upcoming trial, which will test the combined use of NaviFUS System with chemotherapy drug. The NaviFUS System is noninvasive and can greatly reduce the risk of opening the blood-brain barrier (BBB) while simultaneously enhancing drug delivery to the brain; NaviFUS has completed the paperwork for the upcoming clinical trial application, and after being approved by the TFDA in March 2020, the clinical trial tit...